OverviewSuggest Edit

NovoCure engages in the development, manufacture and commercialization of tumor treating fields for the treatment of solid tumors. The Company markets its proprietary therapy, TTFields delivery system, for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.

TypePublic
Founded2000
HQSaint Helier, JE
Websitenovocure.com
Employee Ratings2.5

Latest Updates

Employees (est.) (Dec 2018)598(+21%)
Job Openings84
Revenue (FY, 2018)$248.1 M(+41%)
Share Price (Oct 2019)$77.1 (+3%)

Key People/Management at NovoCure

Bill Burke

Bill Burke

Global Head HR
Laura Benson

Laura Benson

Vice President Medical Affairs
Moshe Giladi

Moshe Giladi

Head of Preclinical Research
Show more

NovoCure Office Locations

NovoCure has offices in Saint Helier, Atlanta, Boston, Charlotte and in 33 other locations
Saint Helier, JE (HQ)
Grenville St
München, DE
Wörthstraße 7
Chiyoda City, JP
Tower 36th Floor, 1-chōme-9-1 Marunouchi
Root D, CH
D4 Pk. 6
Atlanta, US
Atlanta, GA, USA
Boston, US
Boston, MA, USA
Show all (37)

NovoCure Financials and Metrics

NovoCure Revenue

Embed Graph
View revenue for all periods
NovoCure's revenue was reported to be $248.07 m in FY, 2018
USD

Revenue (Q2, 2019)

86.7m

Gross profit (Q2, 2019)

65.6m

Gross profit margin (Q2, 2019), %

75.7%

Net income (Q2, 2019)

(1.3m)

EBIT (Q2, 2019)

1.2m

Market capitalization (11-Oct-2019)

7.6b

Closing stock price (11-Oct-2019)

77.1

Cash (30-Jun-2019)

180.1m
NovoCure's current market capitalization is $7.6 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

33.1m82.9m177.0m248.1m

Cost of goods sold

20.6m39.9m55.6m80.0m

Gross profit

12.5m43.0m121.4m168.0m

Gross profit Margin, %

38%52%69%68%
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

9.0m13.1m17.9m21.7m34.9m38.4m50.1m52.1m61.5m64.8m73.3m86.7m

Cost of goods sold

5.7m8.0m9.8m11.1m11.7m13.2m15.2m18.2m19.8m18.9m19.8m21.1m

Gross profit

3.3m5.1m8.1m10.6m23.2m25.2m35.0m33.9m41.7m45.8m53.5m65.6m

Gross profit Margin, %

37%39%45%49%67%66%70%65%68%71%73%76%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

119.4m99.8m78.6m140.6m

Accounts Receivable

29.6m36.5m

Inventories

13.6m25.5m22.0m22.6m

Current Assets

293.9m261.9m245.1m321.4m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(111.6m)(131.8m)(61.7m)(63.6m)

Depreciation and Amortization

3.2m5.7m7.7m9.0m

Inventories

(12.0m)

Cash From Operating Activities

(99.9m)(107.6m)(33.1m)(1.9m)
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(78.7m)(35.4m)(40.6m)(33.6m)(18.0m)(39.2m)(50.7m)(20.7m)(15.5m)(11.7m)(12.1m)(13.4m)

Depreciation and Amortization

2.0m1.1m1.4m1.6m1.7m3.5m5.5m2.2m2.3m2.3m1.9m4.1m

Inventories

(7.7m)(2.9m)(4.8m)(2.8m)(400.0k)

Cash From Operating Activities

(73.8m)(31.0m)(29.4m)(33.5m)(26.9m)(32.8m)(30.2m)(16.8m)(7.5m)5.6m(4.3m)4.8m
USDY, 2019

Financial Leverage

2.6 x
Show all financial metrics

NovoCure Online and Social Media Presence

Embed Graph

NovoCure News and Updates

Novocure Chief Science Officer Eilon Kirson to retire after 7 years in the role

Novocure Ltd. said Thursday Chief Science Officer Eilon Kirson will retire after about 7 years in the role, and 17 years with the company. The cancer treatment company said Kirson's retirement provides the opportunity to separate medical and scientific responsibilities. Uri Weinberg, vice president…

NovoCure Blogs

Novocure to Report Third Quarter 2019 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2019 on Thursday, October 31, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial resu…

Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting

The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at one of the premier meetings for radiation oncologists Highlights include a subgroup analysis of the STELLAR trial by radiological response patterns in malignant pleural mesothelioma and the first pre…

NovoCure Frequently Asked Questions

  • When was NovoCure founded?

    NovoCure was founded in 2000.

  • Who are NovoCure key executives?

    NovoCure's key executives are Bill Burke, Laura Benson and Moshe Giladi.

  • How many employees does NovoCure have?

    NovoCure has 598 employees.

  • What is NovoCure revenue?

    Latest NovoCure annual revenue is $248.1 m.

  • What is NovoCure revenue per employee?

    Latest NovoCure revenue per employee is $414.8 k.

  • Who are NovoCure competitors?

    Competitors of NovoCure include PatientsLikeMe, Independa and HealthUnlocked.

  • Where is NovoCure headquarters?

    NovoCure headquarters is located at Grenville St, Saint Helier.

  • Where are NovoCure offices?

    NovoCure has offices in Saint Helier, Atlanta, Boston, Charlotte and in 33 other locations.

  • How many offices does NovoCure have?

    NovoCure has 37 offices.